May 5, 2020 / 5:53 AM / a month ago

BRIEF-Isofol: Arfolitixorin Gets Additional Clinical Patent Approval In US

May 5 (Reuters) - Isofol Medical AB (publ):

* ISOFOL’S DRUG CANDIDATE ARFOLITIXORIN RECEIVES ADDITIONAL CLINICAL PATENT APPROVAL IN THE UNITED STATES

* TODAY ANNOUNCED APPROVAL OF A CLINICAL PATENT FOR ARFOLITIXORIN IN UNITED STATES

* PATENT EXPIRES IN 2038 AND IS A DIVISIONAL PATENT FOR MASTER PATENT GRANTED IN US IN MAY 2019

* NOW GRANTED PATENT (US 10,639,311) IS MORE SPECIFICALLY FOCUSED ON DOSE REGIMEN USED IN ONGOING CLINICAL AGENT STUDY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below